Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06379113 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 2 years later Mar 30, 2026 → Mar 30, 2028
See other at-risk trials from Xiaojun Chen

Record History

  1. Primary completion pushed from Mar 30, 2026 to Mar 30, 2028
    • Study completion pushed from Mar 30, 2027 to Mar 30, 2028
    v4
  2. Primary completion date: Mar 30, 2025 to Mar 30, 2026
    • Study completion date: Mar 30, 2025 to Mar 30, 2027
    v3
  3. Study sites: 1 to 2v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Xiaojun Chen
6 trials monitored
See 2 trials at risk
Obesity
3,874 trials monitored
See 152 trials at risk
Endometrial Cancer
694 trials monitored
See 51 trials at risk
To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
Trial Details
NCT Number NCT06379113
Lead Sponsor Xiaojun Chen
Conditions
(from sponsor)		 Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
Related terms Endometrial Hyperplasia, Endometrial Neoplasms, Obesity, Progesterone Resistance
Enrollment 29 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov